Bispecific Antibody Development Services-Tekbiotech-Yeast Display Service,Phage display technology

Services

Inquiry and ordering

Name*
Phone*
Email*
Product*
Content*

Bispecific Antibody Development Services

Tek Biotech has been developing monoclonal antibodies for over 8 years and has over 8 years of experience in antibody development and the platforms required to engineer antibodies, and has developed different antibody libraries for antibody screening, antibody sequencing, and antibody humanization. Tek Biotech has invested in cutting-edge technologies to produce customized bispecific antibodies using sophisticated engineering, computerized 3-D modeling, and synthetic biology techniques. Starting from the customer's needs, Tek Biotech can help customers design, develop and validate bispecific antibodies for research and preclinical use.

Bispecific antibodies (bsAbs) are antibodies that contain different epitopes (usually at two separate antigenic epitopes) i.e. two antigen binding sites. Typically, one binds specifically to a particular cell surface antigen on the target cell, while the other binds to a "trigger" molecule on the surface of the effector cell, e.g., FcγR or one of the CD3/T cell receptor complexes.

Bispecific antibodies can go beyond the specificity of the effector cell for its natural target and redirect it to kill a target it would otherwise ignore. Different cytotoxicities express different trigger molecules (receptors). Thus, multiple effector responses can be generated against most types of target cells by altering the specificity of the target and effector binding domains. Alternatively, the full range of effector functions (i.e., ADCC, phagocytosis, complement activation, and prolonged serum half-life) can be conferred by specifically targeting one binding to serum immunoglobulins.

Currently, there are two bispecific antibodies on the market for therapeutic use. Due to their different mechanisms of action, bispecific antibodies are gaining attention and more bispecific antibodies are being tested in clinical trials, not only for cancer but also for other diseases.

█ Service Content

Step	Content
Gene synthesis	Generation of up to 3 different designed sequences to generate recombinant antibody DNA plasmids from scratch
Have a try	Generation of bispecific antibody proteins → Small-scale expression into mammalian cell lines → Validation by SDS-PAGE → Binding analysis to recombinant protein antigens by ELISA → Comparison of clones with parental antibodies.
Appraise	Expression of the first 2 full-length bispecific antibodies → binding analysis by ELISA → ELISA evaluation of antibodies recognized by anti-mouse antibodies.
Production	Large-scale antibody production

█ Additional Testing Services

Step	Content
Flow cytometry analysis	Binding analysis of FACS with antigen-positive cell lines
BLI binding analysis	Antibody Binding Affinity Analysis by Octet System Bio-layer Interferometry
Biacore TM SPR Biosensor	Binding and kinetic analysis using Biacore TM SPR biosensor to determine antibody affinity, Ka, Kd, KD values

█ Service Advantages

-- High protein expression in CHO cells

-- Very stable: >2 weeks in serum at 37 °C

-- No solubility issues: > 30 mg/ml

-- Many different stable cell lines with tumor antigens developed to validate many bispecific antibodies

Bispecific Antibody Development Services Frequently Asked Questions

Q: What are bispecific antibodies and what are their special roles in treatment?

A: Bispecific antibodies are a type of antibody that can simultaneously bind to two different antigens. In treatment, this antibody is typically used to precisely target two different pathological markers, which is particularly valuable in cancer therapy as it can simultaneously block growth signals and guide the immune system to attack tumor cells.
Q：What are the main technical challenges in developing bispecific antibodies?

A： The main challenges faced in developing bispecific antibodies include ensuring their high affinity and specificity, avoiding drug cross reactivity, and optimizing their production process to improve yield and purity. In addition, ensuring the stability of antibodies and reducing immunogenicity are also key considerations.
Q：What are the commonly used technical platforms in the design process of bispecific antibodies?

A： Common technology platforms include single chain Fv fragment (scFv) fusion technology, bispecific T cell enhancers (BiTEs), and bivalent antibody platforms. These technologies each have their own advantages, and the appropriate platform is usually selected based on the properties of the target antigen and the required clinical applications.
Q：What are the key steps in the production process of bispecific antibodies?

A： The production of bispecific antibodies typically involves steps such as genetic engineering, establishment of cell lines, protein expression, and purification. The key is to ensure that the expression system can efficiently and stably produce the desired recombinant antibodies, and remove impurities and potential aggregates through appropriate purification methods.
Q：How to evaluate the efficacy and safety of bispecific antibodies?

A： Evaluating the efficacy and safety of bispecific antibodies typically involves in vitro cell experiments and in vivo animal model testing. These studies need to evaluate the binding properties, killing activity, dose dependence, as well as potential toxicity and immune response of antibodies. In addition, preclinical studies also need to follow strict regulatory guidelines to ensure the accuracy and reliability of data.

Q: What are bispecific antibodies and what are their special roles in treatment?

A: Bispecific antibodies are a type of antibody that can simultaneously bind to two different antigens. In treatment, this antibody is typically used to precisely target two different pathological markers, which is particularly valuable in cancer therapy as it can simultaneously block growth signals and guide the immune system to attack tumor cells.
Q：What are the main technical challenges in developing bispecific antibodies?

A： The main challenges faced in developing bispecific antibodies include ensuring their high affinity and specificity, avoiding drug cross reactivity, and optimizing their production process to improve yield and purity. In addition, ensuring the stability of antibodies and reducing immunogenicity are also key considerations.
Q：What are the commonly used technical platforms in the design process of bispecific antibodies?

A： Common technology platforms include single chain Fv fragment (scFv) fusion technology, bispecific T cell enhancers (BiTEs), and bivalent antibody platforms. These technologies each have their own advantages, and the appropriate platform is usually selected based on the properties of the target antigen and the required clinical applications.
Q：What are the key steps in the production process of bispecific antibodies?

A： The production of bispecific antibodies typically involves steps such as genetic engineering, establishment of cell lines, protein expression, and purification. The key is to ensure that the expression system can efficiently and stably produce the desired recombinant antibodies, and remove impurities and potential aggregates through appropriate purification methods.
Q：How to evaluate the efficacy and safety of bispecific antibodies?

A： Evaluating the efficacy and safety of bispecific antibodies typically involves in vitro cell experiments and in vivo animal model testing. These studies need to evaluate the binding properties, killing activity, dose dependence, as well as potential toxicity and immune response of antibodies. In addition, preclinical studies also need to follow strict regulatory guidelines to ensure the accuracy and reliability of data.

Consult Now Bispecific Antibody Development Services